REUTERS: Popular gastric reflux medications may be linked to dem - WDRB 41 Louisville News

REUTERS: Popular gastric reflux medications may be linked to dementia, study says

Posted: Updated:

LOUISVILLE, Ky. (WDRB) -- Have you been taking popular medications like Prilosec to manage your gastric reflux symptoms? If so, you may be placing yourself at risk for dementia, according to a new study by a German research center.

The news agency Reuters is reporting that the German Center for Neurodegenerative Diseases in Bonn, Germany, determined that the repeated use of a certain class of drugs for gastric reflux or peptic ulcers was linked with a higher risk for dementia among patients in Germany.

For more on the Reuters story by Kathryn Doyle, CLICK HERE.

The drugs, known as proton pump inhibitors (PPIs), include lansoprazole (Prevacid), esomeprazole (Nexium), and omeprazole (Prilosec), all manufactured by AstraZeneca.

Representatives of the German Center for Neurodegenerative Diseases state that the can only provide a statistical association between PPI prescriptions and occurrence of dementia in the elderly. It can’t prove that PPIs actually cause dementia.

"The researchers examined medical records from 2004 through 2011 from more than 73,000 patients age 75 and older, mostly women," the Reuters report states. "They classified 2,950 of those patients as regular PPI users, meaning they had at least one prescription for one of the drugs every four or five months over an 18-month period. During the study period, 29,510 people developed dementia."

The conclusion was that regular users of the PPI medications were 44 percent more likely to develop dementia.

For more on the Reuters story by Kathryn Doyle, CLICK HERE.

Copyright 2016 by WDRB News. All rights reserved.

  • Sign Up for WDRB's Sports Newsletter

    * denotes required fields

    Thank you for signing up! You will receive a confirmation email shortly.
Powered by Frankly
All content © Copyright 2000 - 2017 WDRB. All Rights Reserved. For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.